Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck
Autor: | Sylvie Rottey, Desmond Curran, Andrzej Kawecki, Ricard Mesia, Jean-Pierre Delord, Jan B. Vermorken, Ricardo Hitt, D. de Raucourt, Fernando Rivera, Didier Cupissol, Heinz Roland Kienzer, A Gross, Marco Benasso, Carsten Bokemeyer, P. Koralewski |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2010 |
Předmět: |
Oncology
Male Colorectal cancer cisplatin Cetuximab law.invention Carboplatin chemistry.chemical_compound Randomized controlled trial Quality of life law Antineoplastic Combined Chemotherapy Protocols Medicine Aged 80 and over Antibodies Monoclonal Hematology Middle Aged Head and Neck Cancer humanities Survival Rate Treatment Outcome Head and Neck Neoplasms Lymphatic Metastasis Carcinoma Squamous Cell Female Fluorouracil medicine.drug Adult medicine.medical_specialty Antibodies Monoclonal Humanized recurrent and metastatic Internal medicine otorhinolaryngologic diseases Humans Survival rate Aged Neoplasm Staging business.industry Head and neck cancer Original Articles medicine.disease Head and neck squamous-cell carcinoma digestive system diseases Surgery stomatognathic diseases chemistry quality of life Human medicine Neoplasm Recurrence Local business |
Zdroj: | Annals of Oncology Annals of oncology |
ISSN: | 1569-8041 0923-7534 |
Popis: | Background: A phase III trial demonstrated that cetuximab is the first agent in 30 years to improve survival when added to platinum-based chemotherapy (platinum-fluorouracil) first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). This analysis of the trial assessed the impact of treatment on quality of life (QoL). Patients and methods: The European Organisation for Research and Treatment of Cancer QoL Questionnaire-Core 30 (QLQ-C30) and QLQ-Head and Neck 35 (QLQ-H&N35) module were used to assess QoL. Results: Of 442 patients randomly assigned, 291 (QLQ-C30) and 289 (QLQ-H&N35) patients completed at least one evaluable questionnaire. For QLQ-C30, cycle 3 and month 6 mean scores for platinum–fluorouracil plus cetuximab were not significantly worse than those for platinum–fluorouracil. Pattern-mixture analysis demonstrated a significant improvement in the global health status/QoL score in the cetuximab arm (P = 0.0415) but no treatment differences in the social functioning scale. For QLQ-H&N35, the mean score for the cetuximab arm was not significantly worse than that for the chemotherapy arm for all symptom scales at all post-baseline visits. At cycle 3, some symptom scores significantly favored the cetuximab arm (pain, swallowing, speech problems, and social eating). Conclusion: Adding cetuximab to platinum–fluorouracil does not adversely affect the QoL of patients with recurrent and/or metastatic SCCHN. |
Databáze: | OpenAIRE |
Externí odkaz: |